Medicxi wraps up late-stage growth fund at $300 mln
Medicxi has closed its late-stage growth fund at $300 million. Medicx will focus on the European life sciences sector. The investors in Medicxi Growth 1 include Novartis, Verily and the European Investment Fund.
15 June 2017•3 mins read
